A 25-year-old woman with vitiligo universalis, a severe form of vitiligo that causes nearly complete loss of skin color ...

The panelist discusses how emerging targeted therapies like Janus kinase inhibitors and combination treatment approaches are ...

The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025, for reproxalap for patients with dry eye ...

Efforts have been made in recent years to clarify the value of exercise as an adjunctive or independent treatment for major ...

As novel gene therapies emerge, there is a complex interplay among their potential benefits, the burdens they may impose and ...

Roche’s Evrysdi (risdiplam) is the market leader among the drugs for spinal muscular atrophy (SMA). Biogen’s Spinraza ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Kenan R. Omurtag, M.D., discusses how less invasive fertility treatments like lifestyle modifications, ovulation induction ...

Breast cancer treatment settings prove to be a good opportunity to talk about financial toxicity. These conversations can ...

Their results argue for a change to parity between small-molecule agents and biologics when it comes to Inflation Reduction ...